GLP-1 Microdosing: Maintenance, How It Works, and Who Qualifies

You have put in the work, reached your goal weight, and now you are wondering what comes next. Do you stop the medication? Stay on it? Taper down? This is one of the most important decisions in GLP-1 treatment, and the research on what happens after stopping is clear enough that you deserve a straight answer.

This section covers what GLP-1 microdosing actually means, what the evidence says about stopping vs. continuing at lower doses, what to ask a program about lower-dose maintenance, and the emerging (and still early) research on lower-dose GLP-1 applications beyond weight maintenance.

What “microdosing” means in this context

The term “microdosing” in GLP-1 treatment refers to using doses that are lower than the standard therapeutic doses prescribed for active weight loss. It is not an official FDA designation or a clinical protocol – it is a practical term that has emerged from patient communities and providers to describe low-dose, long-term use. Ongoing use below the labeled maintenance doses is off-label, and there is little trial evidence on it.

There are two main reasons someone considers a GLP-1 microdose approach:

Maintenance after goal weight. Active treatment doses are calibrated to produce significant weight loss in patients with obesity or overweight. Once you have reached your goal, the question becomes: what is the lowest dose that maintains the metabolic benefits you have achieved, at a cost and side effect level you can sustain long-term?

Emerging research applications. GLP-1 receptors are expressed in tissue throughout the body – not just the gut and pancreas, but the brain, heart, kidneys, immune system, and elsewhere. Researchers are actively studying lower-dose GLP-1 for effects on inflammation, neurological function, and other applications where the weight loss mechanism is not the primary goal. These are not currently approved indications.

Both contexts are covered in this section.

What happens when you stop: the STEP 4 data

If you are considering stopping GLP-1 medication completely after reaching your goal, you need to understand what the evidence says about what typically happens next.

The STEP 4 trial tested exactly this. Published in JAMA in 2021 (Rubino et al.), STEP 4 enrolled adults who had already completed 20 weeks of semaglutide 2.4 mg for weight management (an average loss of 10.6%) and randomized them to either continue the medication or switch to placebo for the following 48 weeks ^[1].

The result was direct: the people switched to placebo regained an average of 6.9% of body weight, while those who continued lost a further 7.9% on average ^[1]. A separate extension of the STEP 1 trial followed adults who stopped semaglutide after 68 weeks: within a year, they had regained about two-thirds of the weight they had lost ^[2]. The SURMOUNT-4 trial found a similar pattern with tirzepatide: after 36 weeks on the drug, people switched to placebo regained an average of 14.0% of body weight over the next 52 weeks, while those who stayed on it lost a further 5.5% ^[3]. Results vary, and trial results describe study participants, not a prediction for any individual.

This is not a character flaw. It reflects how GLP-1 biology works. GLP-1 is a natural gut hormone that your body produces after meals, signaling satiety to the brain and reducing appetite. GLP-1 medications amplify that signal. When you stop the medication, that amplification disappears. Appetite returns. The biological pressure to eat more reasserts itself. For many people – not all, but many – this means gradual weight regain.

Understanding this biology helps you think clearly about your options. The question is not “have I failed if I need to stay on some form of the medication?” It is “what level of ongoing support makes sense for my body and my goals?”

The maintenance decision: three paths

Once you have reached your goal weight on GLP-1 treatment, three main paths exist:

Path 1: Stop completely. Some patients do maintain their results without ongoing medication, particularly those who have built strong dietary habits and exercise routines during treatment and whose underlying metabolic issues were addressed during treatment. This works for some people. The STEP 4 and STEP 1 extension data tell us it does not work for most. A licensed provider can help you assess your specific situation.

Path 2: Continue full-dose treatment. Remaining on active therapeutic doses indefinitely is a legitimate clinical choice for patients who have obesity-related health conditions that warrant ongoing treatment. This is not the right context for the microdose conversation.

Path 3: Transition to a lower maintenance dose. This is the middle path, and it is where the microdose approach fits. The goal is to maintain the metabolic signal that supports weight stability at the lowest effective dose, which may reduce side effects and, at programs that price by dose, cost. The trials above tested continuing at full doses, not stepping down, so lower-dose maintenance is off-label and rests on limited evidence.

What to check before using a lower maintenance dose

Some telehealth programs offer lower-dose or maintenance plans, and what they include varies. Some bundle medication, provider visits, and labs; others bill separately for labs, dose changes, shipping, or membership fees. Prices vary by program and dose, so compare the total cost: medication, dose changes, provider visits, labs, shipping, membership fees, and cancellation terms.

Lower-dose maintenance usually comes up for two groups:

People who have reached their goal weight with prior GLP-1 treatment and want to transition to a lower-dose maintenance approach rather than stopping completely.

People with prior GLP-1 experience who are interested in lower-dose metabolic support or are exploring GLP-1 at lower doses for reasons beyond active weight loss.

Each program sets its own criteria, and a licensed provider decides whether a lower dose is clinically appropriate.

Transformation Health does not accept payment from providers. How we make money.

What “prior GLP-1 experience” means

Lower-dose maintenance is generally not a starting point for someone new to GLP-1 medications. Maintenance typically follows the titration process, which usually takes several months at standard doses. Prior experience means you and your provider already know how you respond to the medication, and you have built the dietary and lifestyle habits that make maintenance viable.

How provider evaluation works

At most telehealth programs, a licensed provider reviews your health history, your prior treatment course, and your goals before deciding whether a prescription is appropriate. The maintenance context calls for a different clinical assessment than active treatment. Useful questions to ask: how the provider will monitor your weight and side effects, what happens if weight starts to return, and whether the plan uses an FDA-approved product at a labeled dose or a lower, off-label dose.

The microdosing approaches: tirzepatide vs. semaglutide

Both tirzepatide and semaglutide are used in microdose maintenance contexts. The right choice depends on what you were using during active treatment, how you responded, and the clinical judgment of the provider you choose.

Tirzepatide is a dual GIP/GLP-1 receptor agonist: it activates two receptor types rather than one. Its labeled maintenance doses are 5, 10, or 15mg; doses below 5mg for maintenance are off-label, and milligram doses cannot be compared directly between tirzepatide and semaglutide. Read more: Microdosing Tirzepatide.

Semaglutide has a well-characterized dose-response curve and a longer history in clinical practice. Lower doses provide appetite signal without the full weight-loss-level suppression. Some patients maintain comfortably on a fraction of their active treatment dose. Read more: Microdosing Semaglutide.

Specific dosing in the maintenance context is a clinical decision a licensed provider makes based on your individual response, not a protocol you self-select from a chart. That said, understanding the general principles helps you have a better conversation about your options.

Emerging applications: what the research is starting to show

GLP-1 receptors are expressed throughout the body in tissue that goes far beyond the gut. They are found in the brain (particularly in reward circuits and areas involved in mood and cognition), in immune tissue, in the cardiovascular system, and in the kidneys.

This receptor distribution is why researchers are actively studying GLP-1 in contexts that have nothing to do with weight loss. Some of the areas generating the most research interest:

Inflammation and autoimmune conditions

GLP-1 appears to have anti-inflammatory properties. Several research groups are studying lower-dose GLP-1 in conditions involving chronic low-grade inflammation – including certain autoimmune conditions, inflammatory bowel disease, and systemic inflammatory markers. This is early-stage research. There are no current approved indications in this area, and the evidence is not yet at a level that supports clinical recommendations.

Read more: GLP-1 Microdosing for Inflammation and Autoimmune.

Neurological health and cognition

GLP-1 receptors in the brain have made this medication class an active area of interest in neurological research. Observational studies have examined GLP-1 use and rates of cognitive decline. Clinical trials are underway exploring GLP-1 in Alzheimer’s disease, Parkinson’s disease, and other neurological conditions. These are not current indications, and the evidence has not yet reached the threshold for clinical guidance. If this area interests you, a licensed provider can discuss the current state of the research.

Longevity and metabolic health

Some patients – particularly those who have reached a healthy weight and want to maintain the metabolic benefits they experienced during treatment – are interested in the potential long-term metabolic effects of low-dose GLP-1 use. The science here is genuinely interesting, and genuinely early. The evidence base will be clearer in five years than it is today.

None of these emerging applications are approved indications. They are areas of active research interest. Any consideration of GLP-1 outside of current approved uses should be an individual clinical conversation with a licensed provider.

Weight loss plateau: a different context

Some patients searching “GLP-1 microdosing” are actually in the middle of active treatment and experiencing a weight loss plateau. That is a different situation from maintenance, and it has different solutions.

Weight loss plateaus during GLP-1 treatment are normal. They typically reflect metabolic adaptation rather than a problem with the medication. If you have stopped losing weight after several months of treatment, the answer is usually not to lower your dose – it is to assess whether your dose, diet, activity level, or other factors need adjustment. Read more: GLP-1 Weight Loss Plateau: Why It Happens.

What’s in this section

Nine child pages cover the specific aspects of microdosing and maintenance in detail:

• Microdosing Tirzepatide – How tirzepatide is used for maintenance, what lower doses look like in practice, and who benefits most.
• Microdosing Semaglutide – Semaglutide at maintenance doses: the clinical picture and what to expect.
• GLP-1 Microdosing Chart and Schedule – A reference guide to dose ranges used in maintenance contexts.
• Maintenance Dose After Goal Weight – What the transition from active treatment to maintenance looks like, and how a provider determines the right dose.
• Can You Stay on Low Dose After Weight Loss – The evidence on long-term lower-dose maintenance and what it means for you.
• GLP-1 Microdosing for Inflammation and Autoimmune – What the research shows about GLP-1 and inflammation, and the state of evidence for non-weight applications.
• GLP-1 Microdosing FAQ – Common questions about microdosing answered directly.
• Stopping Weight Loss Medication: What Happens – The trial data, what regain looks like biologically, and how to think through the decision.
• GLP-1 Weight Loss Plateau: Why It Happens – What causes a plateau during active treatment and what to do about it.

Back to the GLP-1 Patient Guide.

Citations

[1] Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[2] Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

[3] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/